Treats acute lymphoblastic leukemia (ALL). ANDA 216418, held by Hikma Pharmaceuticals. Mercaptopurine.
As of Nov 21, 2026, ANDA 216418 (Mercaptopurine), held by Hikma Pharmaceuticals, was first approved by FDA on Feb 26, 2025, with 0 approved supplements and 0 published complete response letters.
Mercaptopurine is a nucleoside metabolic inhibitor indicated for the treatment of patients with acute lymphoblastic leukemia (ALL) as part of a combination chemotherapy maintenance regimen. 1.1 Acute Lymphoblastic Leukemia
| Date | Submission | Status | Documents |
|---|---|---|---|
| Feb 26, 2025 | Original application | Approved |
| Product | Active ingredient | Marketing |
|---|---|---|
| Mercaptopurine20MG/ML · suspension;oral | Mercaptopurine | Rx |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. “What FDA's review says” is read by a model (Claude Haiku) from FDA's summary review PDF; a field is shown only if its numbers appear in the review, and each section links the review. Drugs@FDA and FDA complete response letters